ClinicalTrials.gg
RecruitingNCT06743126SUPRAMEUpdated Oct 30, 2026

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

A Phase 3 interventional study of IMA203 and nivolumab plus relatlimab in Melanoma, Cutaneous Malignant and Mucosal Melanoma, sponsored by Immatics US, Inc.. Recruiting at 71 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Immatics US, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Oct 30, 2026Site recruiting status changedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Melanoma, Cutaneous Malignant with a site in United States — 3 open to participants now, 5 under way, 1 of them phase 3. Melanoma, Cutaneous Malignant · United States.

Started
2025
the only one that year
Phase 3
Only one
of the 10
Registered
9th of 10
by date
Lead sponsor
1 of 10
Immatics US, Inc.

Among the 10 studies in Melanoma, Cutaneous Malignant with a site in United States, this one is the only one that started in 2025, is the only one in phase 3, and was the 9th registered.

Melanoma, Cutaneous Malignant

17 studies on the registry are indexed under Melanoma, Cutaneous Malignant; 5 are open to participants now.

Browse Melanoma, Cutaneous Malignant studies →

Open to participants now

3 of the 10 studies in Melanoma, Cutaneous Malignant with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Melanoma, Cutaneous Malignant studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Melanoma, Cutaneous Malignant with a site in United States, or all of them as a file.
02

Study summary

This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma or mucosal melanoma (MM).

For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/

Read the detailed description

SCREENING: Patient eligibility will be determined by protocol inclusion/exclusion criteria including HLA (human leukocyte antigen) screening. Leukapheresis for potential manufacturing of the IMA203 cellular product may be performed, if patients are positive HLA-A*02:01 or one of its P-group alleles and meet the eligibility criteria for leukapheresis.

MANUFACTURING: IMA203 products will be made from the patients' white blood cells.

TREATMENT- Experimental arm: Lymphodepletion with cyclophosphamide and fludarabine will occur in the days before the IMA203 product infusion to improve the duration of time that IMA203 product stays in the body. The T-cell infusion will be administered at an authorized treatment center.

After the IMA203 product infusion, a low dose of IL-2 will be given subcutaneously for up to 10 days.

TREATMENT- Control arm: Investigator's choice of treatment approved by the respective competent authority (nivolumab plus relatlimab [Opdualag®], lifileucel, nivolumab, pembrolizumab, ipilimumab, or chemotherapy [e.g., dacarbazine, temozolomide, paclitaxel, alb-bound paclitaxel, or paclitaxel plus carboplatin]) as determined by the site investigator in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC).

03

Conditions studied

  • Melanoma, Cutaneous Malignant
  • Mucosal Melanoma
04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed and documented cutaneous melanoma or mucosal melanoma. CM patients (including acral melanoma and melanoma of unknown primary) and mucosal melanoma patients with unresectable or disease
  • Positive for HLA-A*02:01 or one of its P-group alleles
  • Adequate selected organ function per protocol
  • (ECOG) performance status 0-1
  • Disease progression (resistance, toxicity) on or after at least one inhibitor, applied either as monotherapy or in combination with other therapies as treatment for unresectable or metastatic melanoma
  • Patients with BRAF mutation should have been treated with one prior line of BRAF-directed therapy (with or without a MEK inhibitor) prior to initial eligibility assessment, unless deemed not clinically indicated at Investigator's discretion due to concurrent medical condition, prior toxicity, or if declined by the patient
  • more than 6 months
  • according to (RECIST 1.1)
  • Female patient of must use adequate from randomization until 12 months after the infusion of IMA203 or in line with the instructions provided for investigator's choice treatment (in the control arm)
  • Male patient must agree to use effective contraception or be abstinent while on study and for 6 months after the infusion of IMA203 or in line with the instructions provided for investigator's choice treatment (in the control arm)
  • The patient must have recovered from any side effects of prior therapy to Grade 1 or lower prior to randomization and prior to trial treatment start.

Exclusion criteria

Exclusion Criteria:

  • Uveal melanoma
  • History of other (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years
  • Serious disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of agents.
  • History of cardiac conditions as per protocol
  • Prior allogenic stem cell transplantation or solid organ transplantation
  • Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study
  • History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician
  • History of to CY, FLU, or IL-2 or presence of any and other limitations for planned treatment with investigator's choice as laid down in the current versions of the respective PIs / SmPCs
  • Known hypersensitivity to any of the rescue medications
  • History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the investigator
  • Positive for infection or with active virus (HBV) or active virus (HCV) infection.
  • Any condition contraindicating leukapheresis
  • Pregnant or breastfeeding
  • Any other condition that would, in the investigator's or sponsor's judgment, contraindicate the patient's participation in the clinical trial because of safety concerns or compliance with clinical trial procedures (e.g., psychiatric disorders or substance dependence, neurological impairment)
  • Patient has received systemic within 2 weeks prior to leukapheresis,
  • Patient has received surgery or other anti-cancer therapies, any agent that is likely to suppress bone marrow function, or medicinal products within 7 days prior to leukapheresis.
  • Patients with any active infection or ongoing reactivation of infection
  • Patients who underwent non-myeloablative lymphodepletion prior to cell therapy within the last 6 months
  • Prior treatment with IMA203
  • Patients with ascites, pleural or pericardial effusion which requires repeated (2 within 4 weeks) or continuous paracentesis, thoracentesis or pericardiocentesis within last 2 months
  • Patients with LDH greater than 2.0-fold
  • Concurrent treatment in another clinical trial or a device study that could interfere with the IMA203 treatment or planned investigator's choice treatment
  • Patients with active or
  • Patient has received any investigational therapies, inactivated vaccines, chronic use of systemic corticosteroids or IV antibiotics within 1 week prior to randomization, or within 4 weeks prior to randomization
  • Patient has received any anti-cancer therapy (prior anti-cancer treatment or bridging therapy) or radiotherapy within 1 week prior to start of trial treatment
  • Other protocol defined inclusion/exclusion criteria could apply
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Experimental arm

    Non-myeloablative chemotherapy for lymphodepletion (LD) over 4 days using fludarabine (FLU) and cyclophosphamide (CY), one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy

    Biological: IMA203

  • Active comparator
    Control arm- investigator's choice

    Investigator's choice of treatment approved by the respective Competent Authority (nivolumab plus relatlimab \[Opdualag®\], lifileucel, nivolumab, pembrolizumab, ipilimumab, or chemotherapy \[e.g., dacarbazine, temozolomide, paclitaxel, alb-bound paclitaxel, or paclitaxel plus carboplatin\]) as determined by the site investigator in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC), optional bridging therapy.

    Biological: nivolumab plus relatlimab · Biological: lifileucel · Biological: nivolumab · Biological: pembrolizumab · Biological: ipilimumab · Drug: Dacarbazine · Drug: temozolomide · Drug: paclitaxel · Drug: paclitaxel plus carboplatin · Drug: Albumin-Bound Paclitaxel

Interventions

  • BiologicalIMA203

    one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy

    Also known as: anzutresgene autoleucel, anzu-cel

  • Biologicalnivolumab plus relatlimab

    Drug pages: Nivolumab · Relatlimab

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

    Also known as: Opdualag®

  • Biologicallifileucel

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

    Also known as: AMTAGVI

  • Biologicalnivolumab

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

    Also known as: Opdivo®

  • Biologicalpembrolizumab

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

    Also known as: Keytruda®

  • Biologicalipilimumab

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

    Also known as: Yervoy

  • in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

    Also known as: DTIC-Dome

  • in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

    Also known as: Temodar

  • in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

    Also known as: Taxol

  • Drugpaclitaxel plus carboplatin

    Drug pages: Paclitaxel · Carboplatin

    in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

    Also known as: Carbo/Taxol®

  • in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)

    Also known as: Abraxane®

06

What researchers measure

Primary outcomes

  1. Progression-free survival assessed by BICR

    progression-free survival (PFS), centrally assessed (by blinded independent central review) using RECIST 1.1

    Time frame: up to 5 years post first treatment of last patient

Secondary outcomes

  1. Overall survival (OS)

    conducted onsite or can be performed by phone

    Time frame: up to 5 years post first treatment of last patient

  2. Objective response rate (ORR)

    complete responses (CR) and partial response (PR) based on best overall response (BOR), locally and centrally (by blinded independent central review) assessed using RECIST 1.1

    Time frame: up to 5 years post first treatment of last patient

  3. Progression-free survival

    Progression-free survival locally assessed using RECIST 1.1

    Time frame: up to 5 years post first treatment of last patient

  4. Treatment-emergent adverse events (TEAEs)

    To evaluate safety and tolerability of treatment with IMA203 compared with control (investigator's choice)

    Time frame: until 85 days after cell therapy treatment or 30 days after last treatment

  5. Adverse events of special interest (AESIs)

    To evaluate safety and tolerability of treatment with IMA203 compared with control (investigator's choice)

    Time frame: until 85 days after cell therapy treatment or 30 days after last treatment

  6. Treatment-emergent serious adverse events (TESAEs)

    To evaluate safety and tolerability of treatment with IMA203 compared with control (investigator's choice)

    Time frame: until 85 days after cell therapy treatment or 30 days after last treatment

  7. Frequency and duration of dose interruptions, reductions, and discontinuations

    To evaluate safety and tolerability of treatment with IMA203 compared with control (investigator's choice)

    Time frame: up to 5 years post first treatment of last patient

  8. EORTC QLQ-C30

    To evaluate the patient-reported quality of life before and after treatment with IMA203 compared with control (investigator's choice)

    Time frame: up to 5 years post first treatment of last patient

  9. EQ-5D-5L

    To evaluate the patient-reported quality of life before and after treatment with IMA203 compared with control (investigator's choice)

    Time frame: up to 5 years post first treatment of last patient

07

Study locations

71 of 71 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2025 (actual). Primary completion is estimated for Jan 2028, 36 months after the start.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2031 → Aug 2032, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Dec 19, 2024
StartActual
Jan 14, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Aug 12, 2032was Oct 2031
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • AdventHealth, Orlando · Orlando, United StatesNot yet recruiting→Recruiting
  • Winship Cancer Institute, Emory University · Atlanta, United StatesNot yet recruiting→Recruiting
  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting · Amsterdam, NetherlandsNot yet recruiting→Recruiting
  • University of Southampton NHS Foundation Trust, Southampton General Hospital · Southampton, United KingdomNot yet recruiting→Recruiting
Oct 30, 2026
Study completion
Oct 2031→Aug 12, 2032
Oct 30, 2026
Enrollment
360→450
Oct 30, 2026
Eligibility
3 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPathologically confirmed and documented cutaneous melanoma- or mucosal melanoma. CM patients (including acral melanoma and melanoma of unknown primary) and mucosal melanoma patients with unresectable or metastatic disease
  • EditedPositive for HLA-A*02:01 positiveor one of its P-group alleles
  • EditedDisease progression (resistance, toxicity) on or after at least one PD-1 inhibitor, applied either as monotherapy or in combination with other therapies as treatment for unresectable or metastatic cutaneous melanoma
Exclusion criteria
  • EditedPrimary mucosal or uvealUveal melanoma
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • AdventHealth, Orlando · Orlando, United StatesNot yet recruiting→Recruiting
    • Winship Cancer Institute, Emory University · Atlanta, United StatesNot yet recruiting→Recruiting
    • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting · Amsterdam, NetherlandsNot yet recruiting→Recruiting
    • University of Southampton NHS Foundation Trust, Southampton General Hospital · Southampton, United KingdomNot yet recruiting→Recruiting
    Study completion Oct 2031→Aug 12, 2032
    Enrollment 360→450
    Eligibility 3 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPathologically confirmed and documented cutaneous melanoma- or mucosal melanoma. CM patients (including acral melanoma and melanoma of unknown primary) and mucosal melanoma patients with unresectable or metastatic disease
    • EditedPositive for HLA-A*02:01 positiveor one of its P-group alleles
    • EditedDisease progression (resistance, toxicity) on or after at least one PD-1 inhibitor, applied either as monotherapy or in combination with other therapies as treatment for unresectable or metastatic cutaneous melanoma
    Exclusion criteria
    • EditedPrimary mucosal or uvealUveal melanoma
    + 3 other changes: verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06743126
Lead sponsor
Immatics US, Inc.
Responsible party
Sponsor
First posted
Dec 19, 2024
Start date
Jan 14, 2025
Primary completion
Jan 2028 (estimated)
Completion
Aug 12, 2032 (estimated)
Last update
Oct 30, 2026

Study contacts

Immatics US, Inc.
Contact
ctgovinquiries@immatics.com
+1 346 204-5400
Cedrik Britten, M.D.
study director · Immatics US, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anzutresgene autoleucel

Start the discussion